|22nd September 2020||Advisors Llc Perceptive||1,058,824||Open or private purchase||$17.00||$18,000,008.00|
|22nd September 2020||Advisors Llc Perceptive||1,644,785||Conversion of derivative||$0.00|
|15th September 2020||Advisors Llc Perceptive||2,911,764||Open or private purchase||$4.25||$12,374,997.00|
|14th September 2020||Advisors Llc Perceptive||1,800,000||Open or private purchase||$11.00||$19,800,000.00|
|14th September 2020||Advisors Llc Perceptive||400,000||Open or private purchase||$40.00||$16,000,000.00|
|10th September 2020||Advisors Llc Perceptive||200,000||Open or private purchase||$11.24||$2,248,000.00|
|9th July 2020||Advisors Llc Perceptive||3,200,000||Open or private purchase||$4.25||$13,600,000.00|
|30th June 2020||Todd C Brady||8,418||Grant/award etc.||$0.00|
|22nd June 2020||Advisors Llc Perceptive||1,750,000||Open or private purchase||$2.00||$3,500,000.00|
|9th June 2020||Advisors Llc Perceptive||2,702,702||Open or private purchase||$1.85||$4,999,998.70|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Aldeyra Therapeutics, Inc. is a biotechnology company. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases.